Contact:Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344Burns McClellan, Inc.Lisa Burns Justin Jackson (Media)Email: email@example.comPhone: 212-213-0006
Today's Intra-Cellular update was probably going to send the stock price falling regardless of how management acted, but the refusal to be transparent made a bad day even worse.
Intra-Cellular Therapies, Organovo Holdings and Acorda Therapeutics were among the biotech stock movers in premarket trading on Monday.
The firms all have drugs they want the feds to bend the rules to approve.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.